Watch INDP. Know when insiders buy.
One email the day a filing lands. Free.
INDP
Indaptus Therapeutics, Inc.
3.16
+0.20 +6.76%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $421MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$15.4MNET CASH —52W 0.94 – 4.75SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$1.8M | −$1.8M | — | -0.02 | −$1.9M | — | — | Aug 13 |
| Q1 2026 · Mar 31 | — | — | — | −$2.2M | −$2.5M | — | -0.23 | −$7M | — | — | Aug 13 |
| Q4 2025 · Dec 31derived | — | — | — | −$8.2M | −$8.1M | — | -3.10 | −$3.2M | — | — | Mar 17 |
| Q3 2025 · Sep 30 | — | — | — | −$2.6M | −$3M | — | -2.98 | −$2.6M | — | — | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$4.5M | −$5.2M | — | -9.09 | −$4M | — | — | Aug 13 |
| Q1 2025 · Mar 31 | — | — | — | −$4.6M | −$4.5M | — | -9.11 | −$5M | — | — | Aug 13 |
| Q4 2024 · Dec 31derived | — | — | — | −$4.2M | −$4.1M | — | -10.43 | −$3.4M | — | — | Mar 17 |
| Q3 2024 · Sep 30 | — | — | — | −$3.1M | −$3.1M | — | -9.04 | −$2.5M | — | — | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$4.1M | −$4M | — | -13.16 | −$2.5M | — | — | Nov 12 |
| Q1 2024 · Mar 31 | — | — | — | −$3.9M | −$3.8M | — | -0.45 | −$3.9M | — | — | Nov 12 |
| Q4 2023 · Dec 31derived | — | — | — | −$4.2M | −$4M | — | -0.47 | −$2.6M | — | — | Mar 13 |
| Q3 2023 · Sep 30 | — | — | — | −$4.2M | −$3.9M | — | -0.47 | −$3.7M | — | — | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$19.8M | −$20.8M | — | -21.58 | −$14.8M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$15.4M | −$15M | — | -44.96 | −$12.3M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$16.4M | −$15.4M | — | -1.83 | −$13.4M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$14.9M | −$14.3M | — | -1.73 | −$13.1M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | −$7.7M | −$7.7M | — | -1.89 | −$11.3M | $4K | −$11.3M | — | — |
| FY2020 · to Dec 31 | — | — | −$3.6M | −$3.6M | — | -1.84 | −$3.3M | — | — | — | — |
Every number comes from Indaptus Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.